NR1H4 and metabolic dysfunction-associated steatotic liver disease: In nonalcoholic fatty liver disease (NAFLD), supplementing rats with 312 mg/kg/day of Eosinophil-Lactobacillus was found to decrease blood lipid and total BA levels while activating farnesoid X receptor (Fxr) and fibroblast growth factor 15 (Tgf15) in the liver.